Data investigation

Where the Evidence Is Strongest

Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

Most of the evidence we examine has something wrong with it: heterogeneity, confounding, exploratory subgroups, thresholds barely cleared. This one is different. In people with chronic kidney disease, a synthesis of 13 trials (97,428 participants, 31,846 of them with confirmed CKD) rates the cardiovascular and kidney benefits at high certainty by GRADE,[1] the top of the scale. We have not been able to write that on this site before.

What the evidence shows

GLP-1 receptor agonists in chronic kidney disease. 13 randomized trials, 31,846 participants with confirmed CKD.[1]
OutcomeEffectCertainty
Major adverse cardiovascular events16% reduction (HR 0.84, 95% CI 0.79–0.89)High
Composite kidney endpoint21% reduction (HR 0.79, 0.73–0.86)High
Kidney failure28% reduction (HR 0.72)—
Urine albumin-to-creatinine ratio26% decrease—
Acute kidney injuryNo excess risk—

That last row matters more than it looks. The obvious mechanistic worry with these drugs in kidney disease is dehydration: vomiting and reduced fluid intake are exactly how someone with impaired kidneys ends up with acute injury. The concern is sensible, and it did not materialize.

The question every CKD patient actually has

Many people with chronic kidney disease and type 2 diabetes now take an SGLT2 inhibitor, which has its own strong kidney evidence. What taking both means day to day is in an SGLT2 and a GLP-1 together. So the practical question is less whether a GLP-1 works than whether it adds anything on top of what someone is already taking.

The benefits held regardless of SGLT2 inhibitor background use, with an interaction P of 0.41. That is the statistic we have used twice before to take apart apparent subgroup differences. Here it does its most useful job, showing that two treatments are additive rather than redundant.

That one number does a lot of work. We covered a case where an interaction P of .06 left a clean-looking split unestablished, in the statistic that asks if groups differ, and a mirror case where values of 0.62, 0.40 and 0.99 showed subgroups behaving alike, in how many people to treat to help one. Here the same test answers a question with money and inconvenience riding on it, and the answer is that the benefit holds on top of an SGLT2 inhibitor.

What 'high certainty' means, and why it is unusual here

GRADE rates evidence on four levels (very low, low, moderate, high) based on risk of bias, consistency, directness, precision and publication bias. High means further research is very unlikely to change the estimate.

Almost nothing we have covered reaches it. The BMJ synthesis of 262 trials rated the newest drugs very low to low. The aspiration meta-analysis was low. The dose-withholding finding was very low. Set against that background, two high-certainty outcomes is a different kind of result.

A review that only ever discounts evidence is as useless as one that only ever promotes it.

The reason this particular question is well answered is not luck. It was studied in dedicated randomized trials, in a defined population, against hard endpoints such as dialysis, transplantation and death, which are counted rather than measured on a scale. That is what produces high certainty, and it is what most questions in this field have not had.

The one figure to hold loosely

Semaglutide ranked highest among the individual drugs, with a SUCRA of 78.4%. SUCRA is a ranking statistic from network meta-analysis, roughly the probability a treatment is among the better options. Rankings of this kind are notoriously unstable, since small changes in the network reorder them, and the authors describe that analysis as exploratory.

The high-certainty finding is about the class. The ranking within it is not, and reading the SUCRA figure as “semaglutide is the best one for kidneys” would be taking the weakest number in the paper as its strongest.

For the trial that anchors this whole area, and the numbers needed to treat it produced, see how many people to treat to help one; for the broader kidney picture, GLP-1s and your kidneys.

Frequently Asked Questions

In chronic kidney disease, yes, with high-certainty evidence. Across 13 trials, they reduced major cardiovascular events by 16% and a composite kidney endpoint by 21%, with kidney failure risk down 28%.
The benefits held regardless of SGLT2 inhibitor background use, with an interaction P of 0.41, which means the two appear additive rather than redundant. That is the practical question for the many people with kidney disease who are already on one.
No excess risk was observed. The concern is reasonable, since vomiting and reduced fluid intake are how impaired kidneys get injured, but it did not appear in these trials.
On the GRADE scale it is the top of four levels, meaning further research is very unlikely to change the estimate. Almost nothing else covered on this site reaches it.
That ranking comes from an exploratory network analysis using a statistic whose orderings are notoriously unstable. The high-certainty finding is about the drug class; the ranking within it is the weakest number in the paper.

References

  1. 1.Kaur R, Singh A. Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis Diabetes, Obesity and Metabolism. 2026. PMID: 42337824.

How Many People to Treat to Help One

Trials report benefit as a percentage, which sounds impressive and tells you nothing about your own odds. FLOW published the number needed to treat instead: 22, 13 and 17 over three years.

7 min read

Tirzepatide vs Dulaglutide: A Real Head-to-Head

13,299 people randomized to one drug or the other, followed four years. Kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, and nausea, vomiting and diarrhea were all more common on tirzepatide.

6 min read

Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1

SGLT2 inhibitors like Jardiance and Farxiga are routinely taken with Ozempic or Mounjaro, and no label forbids it. Sugar and weight effects add up in trials; heart and kidney gains rest on subgroups. The real overlap is dehydration and ketoacidosis.

12 min read

GLP-1s After a Kidney Transplant

A meta-analysis of 54,680 transplant recipients reports mortality nearly halved and kidney function improving. Four studies stand behind the mortality figure, and the size of the benefit is the reason to be careful with it.

6 min read

Does Weight Loss Fake Kidney Numbers?

Estimated kidney function is calculated from creatinine, and creatinine comes from muscle, so weight loss could flatter the number. A trial checked the estimates against a directly measured filtration rate.

7 min read

GLP-1 Drugs and Kidney Stones: What the Labels and Studies Show

No trial was designed to test whether Ozempic, Wegovy, Mounjaro or Zepbound cause kidney stones. Wegovy's label reports urinary stones in 1.2% vs 0.8% on placebo in a heart trial; the other labels are silent. What the cohorts, urine studies and fluid data show.

10 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

HealthRX

Compounded semaglutide at $165/month after a $99 first month

8.2

bmiMD

Starting below a standard dose, with microdose tiers

9.0

YourEra

Semaglutide at $99/month, well below the typical price

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →